Organisation paid for research Program year 2025 Source: CMS Open Payments

Precision Comprehensive Clinical Research Solutions, LLC

Neither a doctor nor a teaching hospital

Research payments

$904,074

28 payments

Through program year 2025, Precision Comprehensive Clinical Research Solutions, LLC is reported as receiving $904,074 in research payments, across 28 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $310,826 8
2024 Research $287,288 5
2023 Research $170,341 11
2022 Research $80,171 3
2021 Research $55,447 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $538,062 14 payments
  2. Ucb SA $115,178 6 payments
  3. AstraZeneca Pharmaceuticals LP $85,011 2 payments
  4. AstraZeneca UK Limited $58,244 2 payments
  5. AstraZeneca AB $55,447 1 payment
  6. Celgene Corporation $52,132 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (Gca) $241,132 4 payments
  2. A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 MG Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien $189,561 2 payments
  3. Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis $85,011 2 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $75,497 3 payments
  5. A Randomized, Double-Blind, Placebo Controlled, 2-Arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (Neptunus-1) $69,571 4 payments
  6. A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus $63,780 2 payments
  7. (CC-99677-AS-001) Phase 2 Ankylosing Spondylitis $52,132 3 payments
  8. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus $49,910 1 payment
  9. A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome $22,649 2 payments
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $21,655 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record